45 related articles for article (PubMed ID: 31725417)
1. Correspondence on 'Molecular profile is a strong predictor of the pattern of recurrence in patients with endometrial cancer' by Luzarraga Aznar et al.
Zhang J; Sun Y
Int J Gynecol Cancer; 2024 Jun; 34(6):967. PubMed ID: 38599783
[No Abstract] [Full Text] [Related]
2. Advancing endometrial cancer management in the era of molecular classification: insights into pattern of recurrence.
De Vitis LA; Multinu F
Int J Gynecol Cancer; 2024 May; 34(5):667-668. PubMed ID: 38589210
[No Abstract] [Full Text] [Related]
3. An integrated prediction model of recurrence in endometrial endometrioid cancers.
Miller MD; Salinas EA; Newtson AM; Sharma D; Keeney ME; Warrier A; Smith BJ; Bender DP; Goodheart MJ; Thiel KW; Devor EJ; Leslie KK; Gonzalez-Bosquet J
Cancer Manag Res; 2019; 11():5301-5315. PubMed ID: 31239780
[No Abstract] [Full Text] [Related]
4. Response to: Correspondence on 'Molecular profile is a strong predictor of the pattern of recurrence in patients with endometrial cancer' by Zhang and Sun.
Bebia V; Luzarraga Aznar A; Cabrera S
Int J Gynecol Cancer; 2024 Jun; 34(6):968. PubMed ID: 38599781
[No Abstract] [Full Text] [Related]
5. BRCA1/2 and Endometrial Cancer Risk: Implications for Management.
Sherman ME; Foulkes WD
J Natl Cancer Inst; 2021 Sep; 113(9):1127-1128. PubMed ID: 33710310
[No Abstract] [Full Text] [Related]
6. Endometrial cancer-is our knowledge changing?
Králíčková M; Vetvicka V; Laganà AS
Transl Cancer Res; 2020 Dec; 9(12):7734-7745. PubMed ID: 35117376
[TBL] [Abstract][Full Text] [Related]
7. Endometrial cancer: Molecular markers and management of advanced stage disease.
Arend RC; Jones BA; Martinez A; Goodfellow P
Gynecol Oncol; 2018 Sep; 150(3):569-580. PubMed ID: 29843906
[TBL] [Abstract][Full Text] [Related]
8. The rise of a novel classification system for endometrial carcinoma; integration of molecular subclasses.
McAlpine J; Leon-Castillo A; Bosse T
J Pathol; 2018 Apr; 244(5):538-549. PubMed ID: 29344951
[TBL] [Abstract][Full Text] [Related]
9. The optimal cut-off value of immunohistochemical parameter P53 for predicting recurrence of endometrial cancer.
Jia M; Jiang P; Hu J; Huang Z; Deng Y; Hu Z
Int J Gynaecol Obstet; 2021 May; 153(2):344-350. PubMed ID: 33237570
[TBL] [Abstract][Full Text] [Related]
10. Molecular markers in recurrent stage I, grade 1 endometrioid endometrial cancers.
Moroney MR; Davies KD; Wilberger AC; Sheeder J; Post MD; Berning AA; Fisher C; Lefkowits C; Guntupalli SR; Behbakht K; Corr BR
Gynecol Oncol; 2019 Jun; 153(3):517-520. PubMed ID: 30910249
[TBL] [Abstract][Full Text] [Related]
11. Women 50 years or younger with endometrial cancer: the argument for universal mismatch repair screening and potential for targeted therapeutics.
Ring KL; Connor EV; Atkins KA; Ricketts W; Kashlan B; Modesitt SC
Int J Gynecol Cancer; 2013 Jun; 23(5):853-60. PubMed ID: 23552806
[TBL] [Abstract][Full Text] [Related]
12. Integration of Clinical and Molecular Features into Prediction Models for Outcomes in Endometrial Cancer.
Miller MD; Devor EJ
Clin Obstet Gynecol; 2020 Mar; 63(1):40-47. PubMed ID: 31725417
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
